Family Medicine & Primary Care Review
eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2025
vol. 27
 
Share:
Send email
Share:
CONTINUOUS MEDICAL EDUCATION (CME)
Review paper

RSV prevention in adults: consensus of experts of Polish scientific societies

Adam Antczak
1
,
Adam Barczyk
2
,
Aleksander Biesiada
3
,
Małgorzata Czajkowska-Malinowska
4
,
Robert Flisiak
5
,
Robert Gil
6
,
Marcin Grabowski
7
,
Aleksander Kania
8
,
Mikołaj Konstanty
9
,
Rafał Krenke
10
,
Ernest Kuchar
11
,
Artur Mamcarz
12
,
Aneta Nitsch-Osuch
13
,
Iwona Paradowska-Stankiewicz
14
,
Jacek Wysocki
15
,
Krzysztof Tomasiewicz
16

  1. Department of General and Oncological Pulmonology, Medical University of Lodz, Lodz, Poland
  2. Department of Pneumology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
  3. Polish Society of Family Medicine, Wroclaw, Poland
  4. Department of Lung Diseases and Respiratory Failure, Kuyavian-Pomeranian Pulmonology Center, Bydgoszcz, Poland
  5. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland
  6. Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
  7. Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
  8. Department of Pulmonology, Jagiellonian University Medical College, Faculty of Medicine, Krakow, Poland
  9. Supreme Pharmaceutical Chamber, Warsaw, Poland
  10. Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland
  11. Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, Poland
  12. 3rd Department of Internal Diseases and Cardiology, Warsaw Medical University, Warszawa, Poland
  13. Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland
  14. Department of Epidemiology, National Institute of Public Health-National Institute of Hygiene in Warsaw, Warsaw, Poland
  15. Chair and Department of Health Prophylaxis, Medical University of Poznan, Poznan, Poland
  16. Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland
Family Medicine & Primary Care Review 2025; 27(3): 353-359
DOI: https://doi.org/10.5114/fmpcr.2025.154536
Online publish date: 2025/09/29
Article file
- 15 FM&PCR 3 25 - CME R - Antczak - 1943 - RSV.pdf  [1.33 MB]
Get citation
 
PlumX metrics:
 
1. Reis J, Shaman J. Retrospective Parameter Estimation and Forecast of Respiratory Syncytial Virus in the United States. PLoS Comput Biol 2016; 12(10): e1005133.
2. Hall CB, Douglas RG, Jr., Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980; 141(1): 98–102.
3. Galanti M, Birger R, Ud-Dean M, et al. Rates of asymptomatic respiratory virus infection across age groups. Epidemiol Infect 2019; 147: e176.
4. Suh M, Movva N, Jiang X, et al. Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009–2019: A Study of the National (Nationwide) Inpatient Sample. J Infect Dis 2022; 226(Suppl. 2): S154–S163.
5. Zheng Z, Warren JL, Shapiro ED, et al. Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups. Pneumonia (Nathan) 2022; 14(1): 6.
6. Drevinek P, Flisiak R, Nemes R, et al. The Role and Value of Professional Rapid Testing of Acute Respiratory Infections (ARIs) in Europe: A Special Focus on the Czech Republic, Poland, and Romania. Diagnostics (Basel) 2024; 14(6): 631.
7. Du Y, Yan R, Wu X, et al. Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: A systematic analysis of the Global Burden of Disease 2019 Study. Int J Infect Dis 2023; 135: 70–76.
8. Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, et al. Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years. J Infect Dis 2023; 228(11): 1528–1538.
9. D’Ambrosio F, Lomazzi M, Moore M, et al. Addressing the Underestimated Burden of RSV in Older Adults in Europe: Epidemiology, Surveillance Gaps, and Public Health Implications. Vaccines (Basel) 2025; 13(5): 510.
10. Osei-Yeboah R, Spreeuwenberg P, Riccio MD, et al. Estimation of the number of RSV-associated hospitalizations in adults in the European Union. J Infect Dis 2023; 228(11): 1539–1548.
11. Recto CG, Fourati S, Khellaf M, et al. Respiratory Syncytial Virus vs Influenza Virus Infection: Mortality and Morbidity Comparison Over 7 Epidemic Seasons in an Elderly Population. J Infect Dis 2024; 230(5): 1130–1138.
12. Ambrosch A, Luber D, Klawonn F, et al. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology and clinical course compared to influenza A/B and the original SARS-CoV-2 strain. J Clin Virol 2023; 161: 105399.
13. Quarg C, Jörres RA, Engelhardt S, et al. Characteristics and outcomes of patients hospitalized for infection with influenza, SARS-CoV-2 or respiratory syncytial virus in the season 2022/2023 in a large German primary care centre. Eur J Med Res 2023; 28(1): 568.
14. Wiechert L, Fischer C, Jörres RA, et al. Characteristics and outcomes of patients hospitalized for infection with Influenza A, SARS-CoV-2 or respiratory syncytial virus in the season 2023/2024 in a large German primary care centre. Eur J Med Res 2024; 29(1): 509.
15. Rozporządzenie Ministra Zdrowia z dnia 23 lutego 2023 r. w sprawie zakażeń wirusem syncytialnym układu oddechowego (RSV) (Dz.U. 2023, poz. 354) (in Polish).
16. Meldunki o zachorowaniach na choroby zakaźne, zakażeniach i zatruciach w Polsce [Internet]. Warszawa: Narodowy Instytut Zdrowia Publicznego – Państwowy Insytytut Badawczy; 2025. Available from URL: https://wwwold.pzh.gov.pl/oldpage/epimeld/index_p.html#01 (in Polish).
17. Hospitalizacje spowodowane zachorowaniami wywołanymi przez syncytialny wirus oddechowy [Internet]. Warszawa: Centrum e-Zdrowia; 2025. Available from URL: https://ezdrowie.gov.pl/portal/home/badania-i-dane/zdrowe-dane/zestawienia/liczba-hospitalizacji-dorosli-rsv (in Polish).
18. Chartrand C, Tremblay N, Renaud C, et al. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis. J Clin Microbiol 2015; 53(12): 3738–3749.
19. Jackowska T, Wrotek A, Beń-Skowronek I, et al. Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant. Pediatr Pol 2024; 99(4): 275–282.
20. Britton A, Roper LE, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥ 60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep 2024; 73(32): 696–702.
21. McClure DL, Kieke BA, Sundaram ME, et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥ 50 years old. PLOS ONE 2014; 9(7): e102586.
22. Sundaram ME, McClure DL, Alonge O, et al. Seasonal Incidence of Medically Attended Respiratory Syncytial Virus Infection from 2015 to 2019 in a Cohort of Adults with High-risk Conditions. Open Forum Infect Dis 2025; 12(4): ofaf166.
23. Belongia EA, King JP, Kieke BA, et al. Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥ 60 Years Old. Open Forum Infect Dis 2018; 5(12): ofy316.
24. Sudnik P, Walsh EE, Branche AR, et al. Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with RSV. Clin Infect Dis 2025: ciaf310, doi: 10.1093/cid/ciaf310. Online ahead of print.
25. Wildenbeest JG, Lowe DM, Standing JF, et al. Respiratory syncytial virus infections in adults: a narrative review. Lancet Respir Med 2024; 12(10): 822–836.
26. Heidecker B, Libby P, Vassiliou VS, et al. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement. Eur Heart J 2025: ehaf384, doi: 10.1093/eurheartj/ehaf384. Online ahead of print.
27. Hewitt R, Farne H, Ritchie A, et al. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis 2016; 10(2): 158–174.
28. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352(17): 1749–1759.
29. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; 2025.
30. Global strategy for asthma management and prevention. Global Initiative for Asthma; 2025.
31. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342(6158): 592–598.
32. Abrysvo – respiratory syncytial virus vaccine (bivalent, recombinant) [Internet]. Amsterdam: European Medicines Agency; 2023. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo.
33. Arexvy – recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E [Internet]. Amsterdam: European Medicines Agency; 2023. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy.
34. mResvia – single-stranded 5’ capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation [Internet]. Amsterdam: European Medicines Agency; 2024. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/mresvia.
35. Zeng B, Liu X, Yang Q, et al. Efficacy and safety of vaccines to prevent respiratory syncytial virus infection in infants and older adults: A systematic review and meta-analysis. Int J Infect Dis 2024; 146: 107118.
36. Baber J, Arya M, Moodley Y, et al. A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine with and Without Adjuvant in Healthy Older Adults. J Infect Dis 2022; 226(12): 2054–2063.
37. Ison MG, Papi A, Athan E, et al. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis 2024; 78(6): 17321744.
38. Walsh EE, Pérez Marc G, Falsey AR, et al. RENOIR Trial – RSVpreF Vaccine Efficacy over Two Seasons. N Engl J Med 2024; 391(15): 1459–1460.
39. Fry SE, Terebuh P, Kaelber DC, et al. Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older. JAMA Netw Open 2025; 8(5): e258322.
40. Mensah AA, Whitaker H, Andrews NJ, et al. Early impact of RSV vaccination in older adults in England. Lancet 2025; 405(10485): 1139–1140.
41. Papi A, Ison MG, Langley JM, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med 2023; 388(7): 595–608.
42. Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med 2023; 388(16): 1465–1477.
43. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med 2023; 388(16): 1451–1464.
44. Pérez Marc G, Vizzotti C, Fell DB, et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study. Lancet Infect Dis 2025; 25(9): 1044–1054.
45. Williams TC, Marlow R, Cunningham S, et al. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. Lancet Child Adolesc Health 2025; 9(9): 655–662.
46. Obwieszczenie Ministra Zdrowia z dnia 17 czerwca 2025 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych (Dz. Urz. Min. Zdr. 2025.39) (in Polish).
47. Kalendarz Szczepień Dorosłych [Internet]. Wrocław: Polskie Towarzystwo Medycyny Rodzinnej; 2024. Available from URL: https://ptmr.info.pl/wp-content/uploads/2024/09/HARMONOGRAMSZCZEPIEN_30032024.pdf (in Polish).
Copyright: © 2025 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.